Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. (Nasdaq: ZYME) generates frequent news flow as a biotechnology and clinical-stage biopharmaceutical company managing licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics. Company announcements highlight its focus on difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, and its integrated model that combines internal R&D with an asset and royalty aggregation strategy.
News about Zymeworks often centers on clinical trial progress and key data readouts. A major theme is the development of Ziihera ® (zanidatamab-hrii), a HER2-targeted bispecific antibody engineered using the company’s Azymetric™ technology. Press releases have detailed positive Phase 3 HERIZON-GEA-01 results in first-line HER2-positive gastroesophageal adenocarcinoma, as well as regulatory approvals for previously treated HER2-positive biliary tract cancer in the U.S., Europe, and China. Updates also cover the advancement of partnered programs like pasritamig with Johnson & Johnson Innovative Medicine and early-stage data from wholly owned ADC candidates such as ZW191 and ZW251.
Investors following ZYME news can also expect regular coverage of strategic and corporate developments. The company reports on its evolving royalty- and asset-focused strategy, share repurchase authorizations, milestone and royalty revenues from partners, and leadership and board appointments designed to support capital allocation and partnership execution. Participation in major medical and investor conferences, such as ASCO GI and the J.P. Morgan Healthcare Conference, is another recurring topic in its news releases.
This news feed provides a centralized view of Zymeworks’ clinical milestones, partnership updates, financial and strategic announcements, and governance changes, offering context for how the company is executing its stated goal of building a diversified portfolio of revenue-generating healthcare assets alongside an active R&D engine.
Zymeworks (NASDAQ:ZYME) announced FDA clearance of its Investigational New Drug (IND) application for ZW251, a novel antibody-drug conjugate (ADC) targeting hepatocellular carcinoma (HCC). ZW251 is designed to target glypican-3 (GPC3), which is expressed in over 75% of HCC cases.
The drug represents Zymeworks' second ADC utilizing their proprietary topoisomerase 1 inhibitor payload. Preclinical studies demonstrated strong anti-tumor activity across various HCC models and favorable tolerability in non-human primates at doses up to 120 mg/kg. The company plans to initiate Phase 1 clinical trials in 2025.
Zymeworks (NASDAQ: ZYME), a clinical-stage biotechnology company, has scheduled its second quarter 2025 financial results announcement for August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and provide a corporate update.
Additionally, Zymeworks' management will participate in two upcoming investor conferences: the BTIG Virtual Biotechnology Conference on July 29 and the Stifel Biotech Summer Summit from August 11-13, featuring one-on-one meetings and fireside chat presentations.
Zymeworks (NASDAQ: ZYME) announced multiple presentations at upcoming medical conferences showcasing its oncology portfolio. The presentations will take place at the ASCO Annual Meeting (May 31-June 4, 2025) and ESMO Gynaecological Cancers Congress (June 19-21, 2025).
Key highlights include long-term outcomes and survival data for Ziihera® (zanidatamab-hrii) in HER2-positive gastroesophageal cancer, demonstrating the potential of their Azymetric™ platform. Partner presentations from Jazz Pharmaceuticals, Johnson & Johnson, and Daiichi Sankyo will further validate their expertise in multispecific and bispecific antibodies.
The company will also present Trial-in-Progress posters for two clinical candidates: ZW171 (mesothelin x CD3 targeting bispecific T-cell engager) at ASCO and ZW191 (Folate Receptor α-targeting Antibody-Drug Conjugate) at ESMO-Gyn, with enrollment for both trials progressing as planned.
Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotech company focused on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, has announced its participation in three major upcoming investor conferences in June 2025:
- Jefferies Global Healthcare Conference on June 4 in New York - Management will conduct one-on-one meetings and a fireside chat at 2:35 pm ET
- Goldman Sachs Global Healthcare Conference on June 11 in Miami - Including one-on-one meetings and a fireside chat at 2:00 pm ET
- Citi European Healthcare Conference on June 17 in London - Management will participate in one-on-one meetings
Zymeworks (NASDAQ: ZYME) presented six posters featuring new preclinical data at the 2025 AACR Annual Meeting, showcasing progress in their antibody-drug conjugate and T cell engager platforms. Key highlights include:
- ZW209: A novel T cell engager demonstrating durable activity in small cell lung cancer, with IND submission expected in 1H-2026
- ZW171: A mesothelin-targeting T cell engager in Phase 1 clinical study showing strong anti-tumor activity in lung, ovarian, and pancreatic cancers
- ZW327: A first-in-class Ly6E-targeting antibody-drug conjugate displaying robust anti-tumor activity across various cancer types
The company also presented findings on their biparatopic antibody-drug conjugates targeting PTK7 and developments in 3D tumor models for improved ADC screening.
Zymeworks Inc. (Nasdaq: ZYME) has appointed Dr. Sabeen Mekan as Senior Vice President of Clinical Development to lead the clinical development strategy for its oncology portfolio and global regulatory affairs. Dr. Mekan brings 18 years of experience in hematology and oncology across academic research, clinical practice, and biopharmaceutical industry development.
The company also announced organizational changes with Dr. Jeff Smith continuing as Executive Vice President & Chief Medical Officer, focusing on autoimmune and inflammatory disease R&D portfolio, while Barbara Schaeffler has been promoted to Senior Vice President of Clinical Development Operations.
Dr. Mekan's previous roles include Executive Director at Gilead Sciences, Senior Medical Director at Daiichi Sankyo, and Medical Director at Bristol-Myers Squibb. She will support Zymeworks' development of next-generation antibody-drug conjugates and multispecific antibody therapeutics for gynecological, thoracic, and digestive system cancers.
Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after market close on May 8, 2025, followed by a conference call and webcast at 4:30 pm Eastern Time on the same day. Management will provide both financial updates and a corporate overview during the call.